

## Claims

1. An agent for promoting corneal neuritogenesis, which comprises a Rho protein inhibitor.
- 5  
2. An agent for promoting extension of corneal nerve axon, which comprises a Rho protein inhibitor.
- 10  
3. An agent for the recovery of corneal sensitivity, which comprises a Rho protein inhibitor.
4. A therapeutic agent for dry eye, which comprises a Rho protein inhibitor.
- 15  
5. A pharmaceutical composition for promoting corneal neuritogenesis, which comprises a Rho protein inhibitor.
6. A pharmaceutical composition for promoting extension of corneal nerve axon, which comprises a Rho protein inhibitor.
- 20  
7. A pharmaceutical composition for the recovery of corneal sensitivity, which comprises a Rho protein inhibitor.
- 25  
8. A pharmaceutical composition for the treatment of dry eye, which comprises a Rho protein inhibitor.
9. Use of a Rho protein inhibitor for the production of a pharmaceutical composition for promoting corneal neuritogenesis.
- 30  
10. Use of a Rho protein inhibitor for the production of a pharmaceutical composition for promotion of extension

of the corneal nerve axon.

11. Use of a Rho protein inhibitor for the production of  
a pharmaceutical composition for the recovery of corneal  
5 sensitivity.

12. Use of a Rho protein inhibitor for the production of  
a pharmaceutical composition for the treatment of dry  
eye.

10

13. A method of promoting corneal neuritogenesis, which  
comprises administering an effective amount of a Rho  
protein inhibitor to a subject in need of the promotion  
of the corneal neuritogenesis.

15

14. A method of promoting extension of corneal nerve  
axon, which comprises administering an effective amount  
of a Rho protein inhibitor to a subject in need of the  
promotion of extension of the corneal nerve axon.

20

15. A method of recovering corneal sensitivity, which  
comprises administering an effective amount of a Rho  
protein inhibitor to a subject in need of the recovery  
of corneal sensitivity.

25

16. A method of treating dry eye, which comprises  
administering an effective amount of a Rho protein  
inhibitor to a subject affected with dry eye.